Group 1: Clinical Trial Results - Eli Lilly announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib), showing a significant improvement in event-free survival for early-stage non-small cell lung cancer patients [1][2] - The trial demonstrated that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer [2][4] - This trial is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy, highlighting the importance of genomic testing in cancer treatment [3] Group 2: Safety and Enrollment - The overall safety profile of selpercatinib was consistent with previous studies, with detailed results expected to be presented at an upcoming medical congress [4] - The trial enrolled 151 patients who received either selpercatinib or placebo, marking a significant advancement in the treatment of early-stage lung cancer [4] Group 3: Market Performance and Stock Analysis - Eli Lilly shares have increased by 21.33% over the past 12 months, indicating a strong upward trend, and the stock is currently trading above its key support level of $1033.50 [6] - The stock is positioned closer to its 52-week highs than lows, suggesting continued strength in its price action [6] - The stock carries a Buy Rating with an average price target of $1141.70, with recent analyst upgrades from Deutsche Bank, JP Morgan, and Cantor Fitzgerald [8]